Europe
27 November 2025 The Court of Appeal has overturned a ruling that revoked the pharma company’s cholesterol-lowering antibody patent, clarifying key principles for assessing inventive step.
27 November 2025
24 November 2025
21 November 2025
20 November 2025
18 November 2025
Latest Features
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Europe
In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.
Europe
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger.
Biotechnology
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
Biotechnology
Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight.
Big Pharma
Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
More News
14 November 2025 In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.
13 November 2025 Inconsistent Bolar interpretations and tougher trial disclosures are tightening the squeeze on innovators in life sciences, counsel told LSPN Europe. Tom Phillips reports.
11 November 2025 Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports.
11 November 2025 Cosmetics companies are increasingly using biological molecules in product applications but will need to draft patent applications carefully in this ‘grey area’.
28 October 2025 The tech is being used to crunch thousands of documents in billion-dollar mediations and emerging as a valuable party at the table, finds Muireann Bolger.
22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
17 October 2025 A US Senate subcommittee hearing on patent eligibility reform has David Kappos, former USPTO director, believing that “there’s a better chance than ever” of a pending bill becoming law, finds Sarah Speight.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox